Clinical trials
Open Label clinical trials
Below are recruiting open label clinical trials, each written for real people, not researchers. We’re tracking 367 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06234007RecruitingPhase 2
Short radiation plus combo therapy for advanced rectal cancer
This trial tests a short course of radiation therapy followed by a combination of three drugs (fruquintinib, adebrelimab, and CAPOX chemotherapy) before surgery for people with locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
WuhanAges 18–75 - NCT06301776Recruiting
Shorter vs. longer blood thinners after bridge stent for neck artery
This trial compares two different lengths of blood-thinner therapy after getting a Bridge stent for a narrowed artery in the back of the neck. It aims to find the best way to prevent future strokes with fewer side effects.
Shenyang, LiaoningAges 18–80 - NCT06318897RecruitingPhase 2
Immunotherapy with chemo for early triple-negative breast cancer
This trial tests a combination of an immunotherapy drug (pembrolizumab) plus two chemotherapy drugs (carboplatin and paclitaxel) given before surgery for people with early-stage, triple-negative breast cancer. The goal is to see if this treatment helps shrink or eliminate the tumor before it's removed.
Houston, TexasAges 18 years+ - NCT07357597RecruitingPhase 4
Preventing mouth sores during breast or lung cancer treatment
This trial tests whether a steroid mouthwash can prevent mouth sores caused by the drug Datopotamab Deruxtecan (Dato-DXd). It is for people with certain types of advanced breast cancer or lung cancer who are about to start Dato-DXd for the first time.
Tucson, ArizonaAges 18 years+ - NCT06326645RecruitingEarly Phase 1
Study of crofelemer for short bowel syndrome
This study tests an oral drug called crofelemer in people with short bowel syndrome who need IV fluids or nutrition at least three times a week. The goal is to see if it helps reduce the need for IV support.
Cleveland, OhioAges 18 years+ - NCT06327100RecruitingPhase 1/Phase 2
Tasquinimod for myelofibrosis after JAK inhibitor failure
This trial tests a new drug called tasquinimod, either alone or combined with ruxolitinib, for people with myelofibrosis. It's for patients who haven't gotten enough help from standard treatments or who can't take them.
Houston, TexasAges 18 years+ - NCT06328777RecruitingPhase 1/Phase 2
CABA-201 CAR T Cells For Systemic Sclerosis
This trial tests a new treatment called CABA-201, a type of CAR T cell therapy that targets a protein called CD19 on immune cells. It aims to calm the overactive immune system in people with Systemic Sclerosis and may help stop or slow damage to skin, lungs, and other organs.
New Haven, ConnecticutAges 18–75 - NCT06328712RecruitingPhase 1/Phase 2
Cell therapy for Charcot-Marie-Tooth type 1A (CMT1A)
This trial tests a new cell therapy called EN001 for people with CMT1A. It aims to see if the treatment is safe and can help with nerve function and muscle weakness.
GyeongjuAges 19 years+ - NCT06342544RecruitingPhase 3
Steroids and rituximab to prevent myasthenia from spreading
This trial tests whether a combination of steroid medicine (corticosteroid) and a targeted immune drug (rituximab) can prevent mild eye-muscle weakness from spreading to other muscles. It is for people newly diagnosed with ocular myasthenia who have not yet taken immune-suppressing treatments.
BordeauxAges 18 years+ - NCT06343402RecruitingPhase 1
Study of BBO-8520 for advanced KRAS G12C lung cancer
This trial tests a new oral medication called BBO-8520 for advanced lung cancer with a specific gene change (KRAS G12C mutation). It aims to see if the drug is safe and effective, and may be combined with another drug (pembrolizumab) in some groups.
Birmingham, AlabamaAges 18 years+ - NCT06344416Recruiting
Ribociclib adherence study with smart pill dispenser
This study is testing a new smart pill dispenser (called ReX) to help people with advanced breast cancer take their ribociclib medication regularly. You will answer simple questions about how you feel, and the device will track your medication use.
Minneapolis, MinnesotaAges 18 years+ - NCT06350097RecruitingPhase 3
Osimertinib with or without another drug for advanced EGFR-mutant lung cancer
This trial tests whether adding a new drug (datopotamab deruxtecan) to the standard targeted therapy osimertinib works better for advanced non-small cell lung cancer with certain EGFR mutations. It is for people who have not had chemotherapy or targeted therapy before.
Fountain Valley, CaliforniaAges 18 years+ - NCT06350786Recruiting
Using a placebo to help reduce opioid pain medication
This trial tests whether a special placebo pill, given with your knowledge, can help you reduce your opioid pain medication. You'll work with your own doctor to safely lower your dose while taking the placebo.
Zurich, Canton of ZurichAges 18 years+ - NCT06351514RecruitingPhase 3
Accelerated brain stimulation for negative symptoms of schizophrenia
This trial tests a faster form of brain stimulation called accelerated intermittent theta burst stimulation to help with persistent negative symptoms of schizophrenia. Negative symptoms include things like lack of motivation, reduced emotion, or social withdrawal.
SingaporeAges 21–65 - NCT06389799RecruitingPhase 2
Pemigatinib and Retifanlimab for Advanced Liposarcoma
This trial tests two experimental drugs (pemigatinib and retifanlimab) for advanced dedifferentiated liposarcoma that has not responded to other treatments. It aims to see if this combination can shrink tumors or slow cancer growth.
OsloAges 18–100 - NCT06425380Recruiting
Resistant potato starch for liver cirrhosis and confusion
This study is testing whether a special type of starch (resistant potato starch) can help people with cirrhosis who have had episodes of confusion from liver problems. It may help by changing the bacteria in your gut, which could reduce the risk of future confusion episodes.
Rochester, MinnesotaAges 18–99 - NCT06442423RecruitingPhase 1
Psilocybin study for people with psychiatric symptoms
This trial tests if psilocybin, a substance found in certain mushrooms, can help people with various mental health symptoms that affect daily life. You would take a single dose in a supervised setting and be monitored for changes in your mood and well-being.
New Haven, ConnecticutAges 18 years+ - NCT06447025RecruitingPhase 2
Study of CTI-1601 for people with Friedreich's ataxia
This trial tests an injectable medicine called CTI-1601 for Friedreich's ataxia (FRDA). It is an open-label study, meaning everyone knows they are getting the drug. The study is for people who have taken CTI-1601 before (without serious side effects) or are new to the drug.
Los Angeles, CaliforniaAges 2–60 - NCT06455449RecruitingPhase 3
Injectable anifrolumab for polymyositis or dermatomyositis
This study tests a new injectable medicine (anifrolumab) added to your usual treatments for polymyositis or dermatomyositis. It may help reduce disease activity if you have moderate to severe symptoms and are already on stable therapy.
Phoenix, ArizonaAges 18–75 - NCT06464588RecruitingPhase 1
Testing safety of newborn stem cells for dilated cardiomyopathy in young adults and children
This study tests whether a single intravenous infusion of stem cells from donated newborn tissue is safe for people aged 4 to 39 with dilated cardiomyopathy (a weakened, enlarged heart). It aims to find a new option for those who haven't improved enough with standard heart failure medications.
Atlanta, GeorgiaAges 4–40 - NCT06467500RecruitingPhase 2
Cadonilimab plus chemo for lung cancer after immunotherapy
This trial tests a new drug called cadonilimab combined with chemotherapy for people with advanced lung cancer who have already tried and failed immunotherapy. It aims to see if this combination can help when standard immunotherapy no longer works.
YichangAges 18–75 - NCT06481566Recruiting
Almonertinib plus radiation for EGFR-mutant lung cancer
This trial tests combining a targeted pill (almonertinib) with precise radiation to the lung for people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination works better than the pill alone.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06488625RecruitingPhase 2/Phase 3
Nicotinamide for mild to moderate ulcerative colitis
This trial tests whether a special oral form of nicotinamide (a type of vitamin B3) can help control mild to moderate ulcerative colitis. The pill is designed to release the medication in the lower part of your gut, where UC often affects. Participation involves taking the study drug and having regular checkups to see how your symptoms and inflammation respond.
Kiel, Schleswig-HolsteinAges 18–80 - NCT06488924RecruitingPhase 1/Phase 2
Study of JR-446 for Sanfilippo syndrome type B
This trial tests an experimental drug, JR-446, for children with Sanfilippo syndrome type B (MPS IIIB). The goal is to see if it is safe and can help with symptoms.
HiroshimaAges Up to 17 years
Hear when a new Open Label trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for open label?
- Yes. Clin2 currently lists 367 recruiting open label studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a open label trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a open label trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.